Drug
Crinecerfont
Crinecerfont: highest development phase Phase 3, developed by Neurocrine Biosciences. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Neurocrine Biosciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| Crinecerfont NCT04806451 | Phase 3 | Congenital Adrenal Hyperplasia |
| Crinecerfont NCT04045145 | Phase 2 | CAH - Congenital Adrenal Hyperplasia |
| Crinecerfont NCT07536269 | Phase 2 | Congenital Adrenal Hyperplasia |
| Crinecerfont NCT07187375 | Phase 2 | Congenital Adrenal Hyperplasia |
Latest
No recent events.
Follow Crinecerfont on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.